Full-Time
Key Account Manager
Advanced Lung Disease
United Therapeutics Corporation
Biotech company develops PAH therapies
No salary listed
California, USA
Remote
Remote within California, with up to 75% travel required, mostly in-state.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to United Therapeutics Corporation
See people who can refer or advise you
- A Bachelor's Degree, preferably in nursing or life science.
- At least 12 years of experience within pharmaceutical, specialty pharmaceutical, or biotech marketplaces successfully selling to specialist physicians, nurses, and other healthcare professionals, including cardiologists and pulmonologists.
- At least 8 years of experience in cardiovascular and/or pulmonary disease therapeutic areas.
- At least 5 years of experience in specialty pharmaceutical or biotech sales.
- At least 3 years of experience selling pharmaceutical products distributed through specialty pharmacies.
- At least 3 years of experience working with hospital pharmacies.
- At least 5 years of experience selling within institutional or major teaching-center environments, or at least 3 years of experience working with integrated delivery networks.
- A valid, in-state driver's license.
- A track record of selling excellence in hospitals and academic centers.
- The ability to navigate complex health systems, integrated delivery networks, and multi-stakeholder account environments.
- Demonstrated decision-making, planning, and interpersonal skills.
- Strong execution of marketing strategies and utilization of marketing resources, including educational speaker programs.
- Demonstrated territory management skills.
- Proficiency with Microsoft Office Suite.
- The ability to collaborate with teammates across various departments.
- Expert-level knowledge of United Therapeutics products and services.
- Develop and execute strategic account plans across large academic centers, integrated delivery networks, and specialty clinics to drive Tyvaso adoption and growth.
- Serve as a collaborative partner focused on positive health impact and regional sales growth.
- Serve as an educational resource and partner for healthcare professionals in the assigned geography.
- Serve as a center- and institution-based, key-opinion-leader-driven partner to hospital systems, hospital pharmacies, and other departments.
- Serve as the primary strategic point of contact across designated accounts and health systems within the region to increase education and awareness of pulmonary hypertension associated with interstitial lung disease and idiopathic pulmonary fibrosis, and drive adoption of Tyvaso for approved indications.
- Build and maintain professional relationships with physicians, nurse practitioners, physician assistants, registered nurses, pharmacists, and specialty distributor staff.
- Achieve or exceed company-assigned goals.
- Partner with the regional team to shape engagement strategies at centers of excellence, key teaching hospitals, and fellowship programs.
- Identify and coordinate opportunities across affiliated hospitals, academic centers, pharmacies, and health-system networks to support regional account strategies.
- Develop and execute account plans across complex institutions and map stakeholders across selected institutions within the region.
- Analyze sales reports and develop business plans to increase disease awareness and product adoption.
- Coordinate activities with regional business directors, medical disease directors, clinical pharmacy specialists, and market access team members to support product and disease education, product use, and product access objectives.
- Provide routine stakeholder updates through quarterly business plans and reviews.
- Use available resources effectively to drive sales with key customers.
- Develop and maintain expert knowledge of the disease state, product, and competitive landscape.
- Use the sales-force automation system to maximize territory effectiveness and maintain records.
- Complete United Therapeutics administrative requirements, including expense reports and call reporting, in a timely manner.
- Comply with reporting requirements in the United Therapeutics Commercial Compliance Guidelines.
- Adhere to corporate, external regulatory, and United Therapeutics guidelines related to product promotion.
- Manage the assigned budget and accurately track territory expenses, including travel, speaker-program budget, and home-office expenses.
- Attend local, regional, and national pulmonary hypertension and interstitial lung disease symposia and conferences as required to provide education and promotional support and enhance understanding of treatment trends.
- Engage with the pulmonary hypertension and interstitial lung disease community through approved educational programs and awareness events in accordance with company guidelines.
- Participate, as directed, in project teams with sales and marketing teams to establish programs and resources that increase Tyvaso sales and awareness.
United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.
Company Size
N/A
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
1996
Get referred to United Therapeutics Corporation
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 Tyvaso DPI grew 4%, offsetting declines in nebulized Tyvaso and Remodulin.
- United Therapeutics bought Thymmune on July 2, 2026, broadening transplant-tolerance and immune programs.
- August 2026 Merrimack purchase adds 300 acres for 3D organ and manufacturing expansion.
What critics are saying
- Tyvaso nebulized sales fell 18% in Q2 2026, exposing franchise cannibalization.
- LungFX deployment starts in 2027, delaying revenue while development spending continues.
- Xenotransplantation remains existentially unproven; any FDA trial failure cripples Rothblatt's organ-manufacturing thesis.
What makes United Therapeutics Corporation unique
- United Therapeutics runs FDA-approved PAH brands, plus proprietary LungFX and xenotransplant platforms.
- LungFX earned FDA PMA on June 29, 2026 for centralized ex vivo lung perfusion.
- Its Stewartville DPF facility opened August 12, 2026, scaling gene-edited pig organs.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
401(k) Retirement Plan
401(k) Company Match
Paid Time Off
Paid Holidays
Paid Vacation
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Elder Care Support
Wellness Program
Mental Health Support
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Conference Attendance Budget
Professional Development Budget
Professional Certification Support
Tuition Reimbursement
Stock Options
Company Equity
Employee Stock Purchase Plan
Relocation Assistance
Employee Referral Bonus
Performance Bonus
Profit Sharing
Sabbatical Leave
Hybrid Work Options
Remote Work Options
Flexible Work Hours
ParentAL Leave
Company News
Did Dolly die of her own advice? The independents. Dolly Parton put $1 million into Vanderbilt's early Moderna-related research, sang "Vaccine, vaccine, vaccine, vaccine" to the tune of Jolene, told "cowards" not to be a "chicken squat" - and died at 80 after a brief battle with cancer her team never named. This episode is not a coroner's report. It's about the advice, the playbook, and people on a ship who now say they regret the shot. Self-ownership is the relationship to yourself. Informed consent is the relationship to everyone else. COVIDmania smashed both: hide the downside, ban the question, mandate the product, zero manufacturer liability - then call it a "choice." Also on this show: the Tom Woods cruise, a note from every dinner table (regret vs blame), Fauci-world "delete this, then delete it from trash," and the old Anheuser-Busch campus in Merrimack sold to United Therapeutics, a company specializing in rare-disease work, xenotransplantation, organ printing. Not a data center. Worth eyeballs. If you own the body, you own the guess. The state does not live with the side effects. You do. carlagericke.com Chapters 0:00 Live from the Free State 0:38 Back from holiday / pledge from the porch 1:12 What's on the show 2:01 Merrimack campus sold - United Therapeutics 4:41 Did Dolly die of her own advice? 6:06 Why Dolly still mattered 7:35 Tom Woods cruise 10:43 Regret on the boat 13:25 Vaccines as the frame for self-ownership 16:05 My body, my choice - until it wasn't 17:32 Self-ownership vs informed consent 19:13 The celebrity playbook 20:13 Experimental + no liability = not consent 21:28 What happens when the experts are wrong 23:33 Three conditions for real consent 26:31 Should this go in my body? 27:38 Latency, the kicked can, closing #DollyParton #InformedConsent #SelfOwnership #Covid #NewHampshire #FreeState #TomWoods #Independence #CarlaGericke #Covidmania BONUS! What is xenotransplantation? Xenotransplantation is putting an organ or tissue from one species into another. In the news it almost always means pig | human. Not sci-fi printing from scratch. A pig is bred (usually gene-edited so the human immune system is less likely to attack the organ), the kidney or heart is taken out, and surgeons sew it into a person who would otherwise die waiting for a human donor. Why they want it Human organs are scarce. Thousands die on waitlists. A pig organ is a proposed spare. Why it sounds "sus" * Animal viruses riding along (PERVs - pig viruses) * Immune rejection, even with edits * First patients have been last-ditch cases; some lived weeks or months, not a settled spare-parts aisle * Ethics: breeding animals as organ farms * "Organ printing" is a different pitch (cells + scaffold in a lab). Companies sometimes sell both stories on one campus. United Therapeutics angle They work on lungs/pulmonary disease and have been in the pig-organ / bioengineered-organ lane. Buying a big campus does not mean Merrimack is growing chimeric zombies. It means a firm that wants to industrialize replacement parts now has square footage. One-line for air Xeno = animal organ in a human. The bet is pigs. The risk is viruses, rejection, and a factory logic for bodies. Worth watching. Not the same sentence as "they printed a person."
Anheuser-Busch plant in Merrimack sold to United Therapeutics for $47.5M. * DAVID LANE/UNION LEADER The Anheuser-Busch Merrimack Brewery site (shown here on Wednesday) was sold to United Therapeutics Corporation.
Stewartville's xenotransplant pig facility is ready for animals. United Therapeutics Corp.'s new $110 million "Designated Pathogen-Free" facility is completed in Stewartville's Schumann Business Park and ready to start raising gene-edited pigs to provide transplant organs for humans. Today at 6:25 AM News Reporting STEWARTVILLE, Minn. - A new $110 million "Designated Pathogen-Free" facility is complete and ready to start raising gene-edited pigs to provide transplant organs for humans. United Therapeutics Corp., a $14 billion Maryland-based biotech company behind the first successful pig-to-human heart and kidney transplants, recently hosted a private ribbon-cutting to unveil its newly built complex in Stewartville's Schumann Business Park. Keep Watching First-ever outdoor volleyball match in Minnesota finishes indoors The complex is called the Thomas E. Starzl Xenograft Production Facility in honor of the man who is known as the "Father of Organ Transplantation." Rodney Lam, associate vice president of Xeno Technical Operations with United Therapeutics, explained as he walked the 65,000-square-foot facility that it is now ready for pigs, with a capacity of 150 animals. A team of about 25 people will operate the Starzl Xenograft Production Facility, which raises the animals in pens that combine features of a high-end hog farm and a sterile clean room. Employees will wear protective suits while working with the animals. All of the equipment and products that enter the animals' clean area are sterilized with a shower of hydrogen peroxide. "Essentially, what we've engineered is a building within a building that is meant to keep it as clean as possible," he said. "Ultimately, we want to maintain a herd that is as clean and healthy as possible, so the pigs can become donors for human patients." The facility features its own labs and veterinarian clinic as well as two surgical units. A 3,600-panel solar farm next to it can produce up to 1.4 megawatts of electricity to help offset the facility's power needs. United Therapeutics conducted the first successful pig-to-human heart transplant in 2022 and the first pig-to-human kidney transplant in 2024. It is currently working with the U.S. Food and Drug Administration on clinical trials of xeno-organs with the goal of having pig-to-human transplants approved by the FDA by the end of the decade. In a world where the demand for organs for life-saving transplant continues to grow, United Therapeutics CEO and founder Dr. Martine Rothblatt is investing millions of dollars to eventually create an unlimited supply of organs. The Stewartville facility is one of three similar xenotransplant sites, with the others in Christiansburg, Virginia, and Houston, Texas. While UT's success is largely built on drugs to treat pulmonary arterial hypertension and a type of pediatric cancer, Rothblatt is committed to solving the need for organs. In addition to the xenotransplant sites, UT also has divisions working on regenerative and 3D printing solutions. "Dr. Rothblatt very much believes in multiple shots on goal," said Lam. In addition to the Starzl Xenograft facility, United Therapeutics paid more than $8.5 million in April to buy 200 acres of open farmland between Stewartville and Rochester along Interstate 90, U.S. Highway 63 and 90th Street Southwest with the goal of adding future facilities to support the nearby Stewartville site.
United Therapeutics presents positive Phase 3 lung disease study data. United Therapeutics will present four oral and four poster presentations at the European Society of Cardiology Congress 2026, 28-31 August in Munich, and at the European Respiratory Society Congress 2026, 5-9 September in Barcelona. Late-breaking analyses from the phase 3 ADVANCE OUTCOMES study indicate ralinepag achieved clinical improvement in a lower-risk pulmonary arterial hypertension population and reduced clinical worsening in PAH patients with connective tissue disease, according to the company. Analyses from the phase 3 TETON program show nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit versus placebo in idiopathic pulmonary fibrosis patients. Additional presentations feature interim ARTISAN data on parenteral treprostinil and preliminary PHINDER findings on screening for pulmonary hypertension associated with interstitial lung disease. In June 2026, the company submitted a New Drug Application for ralinepag and a supplemental New Drug Application for nebulized treprostinil to the U.S. Food and Drug Administration; both agents remain investigational.
Liquidia shares fell more than 4% on Wednesday despite the company's lung disease drug Yutrepia beating second-quarter sales expectations. The treatment generated $170.4 million in sales, growing 31% and surpassing forecasts of $166.4 million. However, the company posted earnings of 74 cents per share, slightly missing expectations of 76 cents. Yutrepia, which launched in June 2025, competes with United Therapeutics' Tyvaso in treating high blood pressure in the lungs. Since launch, Liquidia has received approximately 5,900 new patient prescriptions, with more than 5,000 patients starting treatment. Over 1,100 physicians now prescribe the drug. Liquidia stock has gained 155% year-to-date and ranks second on the IBD 50 list of elite growth stocks.